JP2007153892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007153892A5 JP2007153892A5 JP2006323796A JP2006323796A JP2007153892A5 JP 2007153892 A5 JP2007153892 A5 JP 2007153892A5 JP 2006323796 A JP2006323796 A JP 2006323796A JP 2006323796 A JP2006323796 A JP 2006323796A JP 2007153892 A5 JP2007153892 A5 JP 2007153892A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- solvate
- agent
- pharmaceutical composition
- cell growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 5
- 230000010261 cell growth Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- -1 2,3-dihydro-2-oxo-1H-indol-5-yl Chemical group 0.000 claims 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 239000013059 antihormonal agent Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000003080 antimitotic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000003495 polar organic solvent Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000005490 tosylate group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74125205P | 2005-12-01 | 2005-12-01 | |
| US60/741,252 | 2005-12-01 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012220359A Division JP2012255038A (ja) | 2005-12-01 | 2012-10-02 | 異常な細胞増殖の治療用のピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007153892A JP2007153892A (ja) | 2007-06-21 |
| JP2007153892A5 true JP2007153892A5 (enExample) | 2010-11-25 |
| JP5134234B2 JP5134234B2 (ja) | 2013-01-30 |
Family
ID=38092618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006323796A Active JP5134234B2 (ja) | 2005-12-01 | 2006-11-30 | 異常な細胞増殖の治療用のピリミジン誘導体 |
| JP2012220359A Pending JP2012255038A (ja) | 2005-12-01 | 2012-10-02 | 異常な細胞増殖の治療用のピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012220359A Pending JP2012255038A (ja) | 2005-12-01 | 2012-10-02 | 異常な細胞増殖の治療用のピリミジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8722884B2 (enExample) |
| EP (1) | EP1966192B1 (enExample) |
| JP (2) | JP5134234B2 (enExample) |
| AR (1) | AR057202A1 (enExample) |
| CA (1) | CA2632149C (enExample) |
| TW (1) | TWI374880B (enExample) |
| WO (1) | WO2007063384A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| ES2472323T3 (es) * | 2008-06-17 | 2014-06-30 | Astrazeneca Ab | Compuestos de piridina |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
| JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | 選択的ｆａｋ阻害剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5924990B2 (ja) * | 1979-11-21 | 1984-06-13 | 協和醗酵工業株式会社 | 新規なピペリジン誘導体 |
| GB9222700D0 (en) * | 1992-10-29 | 1992-12-09 | Smithkline Beecham Plc | Chemical compounds |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| ES2174462T3 (es) * | 1997-07-29 | 2002-11-01 | Upjohn Co | Formulacion autoestimulante para compuestos lipofilos. |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| AU2002336864B2 (en) * | 2001-11-02 | 2006-08-17 | Shire Biochem Inc. | Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| MXPA06002608A (es) * | 2002-12-20 | 2007-01-23 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP2007537235A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療用ピリミジン誘導体 |
| CA2566332A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2006
- 2006-11-20 EP EP06809250A patent/EP1966192B1/en not_active Not-in-force
- 2006-11-20 WO PCT/IB2006/003349 patent/WO2007063384A2/en not_active Ceased
- 2006-11-20 CA CA2632149A patent/CA2632149C/en active Active
- 2006-11-20 US US12/095,716 patent/US8722884B2/en active Active
- 2006-11-29 AR ARP060105269A patent/AR057202A1/es unknown
- 2006-11-30 TW TW095144504A patent/TWI374880B/zh active
- 2006-11-30 JP JP2006323796A patent/JP5134234B2/ja active Active
-
2012
- 2012-10-02 JP JP2012220359A patent/JP2012255038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2496774C2 (ru) | Гетероциклические ингибиторы аспартильной протеазы | |
| JP2008044952A5 (enExample) | ||
| JP2008512490A5 (enExample) | ||
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| EA200901186A1 (ru) | S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ | |
| EP2412707A3 (en) | 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| RU2009113615A (ru) | Ингибитор киназы | |
| EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| WO2007087204A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia | |
| EP1740559A4 (en) | ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS | |
| JP2006517939A5 (enExample) | ||
| EP2103214A4 (en) | FLOOR OR SEED TREATMENT AGENT CONTAINING A CHINOLINE COMPOUND OR A SALT THEREOF AS ACTIVE SUBSTANCE OR METHOD FOR COMBATING PLANT DISEASES USING THE AGENT | |
| EP1797878A3 (en) | Benzothiazole derivatives | |
| EP3066923A3 (en) | Method of treating chronic kidney disease | |
| JP2010501478A5 (enExample) | ||
| NO332405B1 (no) | Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen. | |
| EP1816122A3 (en) | 3,4,5-substituted piperidines as therapeutic compounds | |
| JP2007510667A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2007537301A5 (enExample) | ||
| WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
| EP1807396A4 (en) | 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| JP2007153892A5 (enExample) | ||
| JP2008513510A5 (enExample) |